0001387131-23-008497.txt : 20230718 0001387131-23-008497.hdr.sgml : 20230718 20230718172436 ACCESSION NUMBER: 0001387131-23-008497 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230630 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230718 DATE AS OF CHANGE: 20230718 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 231095084 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K/A 1 tnxp_8ka-063023.htm AMENDMENT TO FORM 8-K
0001430306 true This Amendment No. 1 to the Original 8-K is being filed to provide the required financial statements under Rule 3-05 of Regulation S-X with respect to the Acquisition. 0001430306 2023-06-30 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

 

FORM 8-K/A

Amendment No. 1

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): June 30, 2023

 

 

 

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction 

of Incorporation) 

(Commission 

File Number)

(IRS Employer 

Identification No.) 

 

26 Main Street, Chatham, New Jersey 07928

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

 

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 

 

Explanatory Note

 

Tonix Pharmaceuticals Holding Corp, Inc. (the “Company”) previously filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission (the “SEC”) on July 3, 2023. The Original 8-K disclosed the acquisition by Tonix Medicines, Inc., a wholly-owned subsidiary of the Company, of Upsher-Smith Laboratories LLC (“Seller”) assets related to Seller’s Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg products (such businesses collectively, the “Business”) and inventory related to the Business (the “Acquisition”).

 

This Amendment No. 1 to the Original 8-K is being filed to provide the required financial statements under Rule 3-05 of Regulation S-X with respect to the Acquisition. Additionally, this report presents the required pro forma financial information reflecting the impact of the Acquisition on the Company.

 

The Company’s results with respect to the Acquisition may be materially different from those expressed in this amended current report due to various factors, including but not limited to those set forth in the Company’s filings with the SEC.

 

Item 9.01 Financial Statements and Exhibits

 

(a) Financial Statements of Businesses Acquired

 

The audited abbreviated statements of assets acquired from Seller, which comprise all of the assets acquired by the Company pursuant to the Acquisition, as of March 31, 2023 and March 31, 2022 and the audited abbreviated statements of net product sales net of direct expenses for the years then ended, and the related notes to abbreviated financial statements are filed herewith as Exhibit 99.01 to this Amendment No. 1 and incorporated by reference into this Item 9.01(a).

 

(b) Pro Forma Financial Information

 

The following unaudited pro forma condensed combined financial information of the Company and the assets acquired from Seller pursuant to the Acquisition are filed herewith as Exhibit 99.02 to this Amendment No. 1 and incorporated by reference into this Item 9.01(b):

 

•Unaudited Pro Forma Condensed Combined Balance Sheet as of March 31, 2023

•Unaudited Pro Forma Condensed Combined Statements of Operations for the three months ended March 31, 2023 and the year ended December 31, 2022

•Notes to Unaudited Pro Forma Condensed Combined Financial Statements

           
Exhibit No. Description
   
23.01 Consent of KPMG LLP
   
99.01 Audited abbreviated financial statements with respect to the Business
   
99.02 Unaudited pro forma condensed combined financial information with respect to the Acquisition of the Business

 

 

 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: July 18, 2023 By: /s/ Bradley Saenger  
  Bradley Saenger
  Chief Financial Officer

 

 

 EX-23.01 2 ex23-01.htm CONSENT OF KPMG LLP
 

Tonix Pharmaceuticals Holding Corp, Inc. 8-K

Exhibit 23.01

 

 

 

 

 

KPMG LLP

4200 Wells Fargo Center
90 South Seventh Street
Minneapolis, MN 55402

  

 

 

Consent of Independent Auditors

 

We consent to the incorporation by reference in the registration statements (Nos. 333-237610, 333-251500, 333-254975, and 333-266982) on Form S-3 and registration statements (Nos. 333-202006, 333-212300, 333-219928, 333-226776, 333-232137, 333-239152, 333-257437, 333-265705 and 333-272746) on Form S-8 of Tonix Pharmaceuticals Holding Corp. of our report dated July 18, 2023, with respect to the abbreviated financial statements of the Tosymra ® and Zembrace ® Symtouch ® Product Lines of Upsher-Smith Laboratories LLC, which report appears in the Form 8-K/A of Tonix Pharmaceuticals Holding Corp. dated July 18, 2023.

 

 

 

 

Minneapolis, Minnesota
July 18, 2023

 

 

 

 EX-99.01 3 ex99-01.htm AUDITED ABBREVIATED FINANCIAL STATEMENTS

 

 

Tonix Pharmaceuticals Holding Corp, Inc. 8-K

Exhibit 99.01

 

Tosymra® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories, LLC

 

Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022

 

With Independent Auditor’s Report Thereon

 

 

 

 

Table of Contents

 

  Page(s)
   
Independent Auditors’ Report 3-4
   
Abbreviated Statements of Assets Acquired as of March 31, 2023 and 2022 5
   
Abbreviated Statements of Net Product Sales Net of Direct Expenses for the years ended March 31, 2023 and 2022 6
   
Notes to the Abbreviated Financial Statements 7-16

 

 

 

 

Independent Auditors’ Report

 

The Board of Directors 

Upsher-Smith Laboratories LLC

 

Opinion

 

We have audited the abbreviated financial statements of the Tosymra® and Zembrace® Symtouch® product lines of Upsher-Smith Laboratories LLC (the Product Lines), which comprise the abbreviated statements of assets acquired as of March 31, 2023 and 2022 and the related abbreviated statements of net product sales net of direct expenses for the years then ended, and the related notes (the Abbreviated Financial Statements).

 

In our opinion, the accompanying Abbreviated Financial Statements present fairly, in all material respects, the assets acquired as of March 31, 2023 and 2022 and the related net product sales net of direct expenses described in Note 2 of the Product Lines for the years then ended, in accordance with U.S. generally accepted accounting principles.

 

Basis for Opinion

 

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Abbreviated Financial Statements section of our report. We are required to be independent of Upsher-Smith Laboratories LLC and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

 

Emphasis of Matter — Basis of Accounting

 

We draw attention to Note 2 to the Abbreviated Financial Statements, which describes that the accompanying Abbreviated Financial Statements were prepared for the purpose of complying with the rules and regulations of the Securities and Exchange Commission (for inclusion in the filing of Form 8-K/A of Tonix Pharmaceuticals Holding Corp.) and are not intended to be a complete presentation of the Product Line’s revenues and expenses. As a result, the Abbreviated Financial Statements may not be suitable for another purpose. Our opinion is not modified with respect to this matter.

 

Responsibilities of Management for the Abbreviated Financial Statements

 

Management is responsible for the preparation and fair presentation of the Abbreviated Financial Statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the Abbreviated Financial Statements that are free from material misstatement, whether due to fraud or error.

 

Auditors’ Responsibilities for the Audit of the Abbreviated Financial Statements

 

Our objectives are to obtain reasonable assurance about whether the Abbreviated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the Abbreviated Financial Statements.

 

 3

 

 

In performing an audit in accordance with GAAS, we:

 

•Exercise professional judgment and maintain professional skepticism throughout the audit.

 

•Identify and assess the risks of material misstatement of the Abbreviated Financial Statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the Abbreviated Financial Statements.

 

•Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control. Accordingly, no such opinion is expressed.

 

•Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the Abbreviated Financial Statements.

 

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control–related matters that we identified during the audit.

 

 

Minneapolis, Minnesota 

July 18, 2023

 

 4

 

 

Abbreviated Statements of Assets Acquired as of March 31, 2023 and 2022

 

    As of March 31,
($ in Thousands)		  
    2023     2022  
             
Inventory   $ 9,472     $ 7,785  
Prepaid assets   $ 1,183     $ 2,630  
Intangible assets, net   $ 0     $ 0  
Total Assets Acquired   $ 10,655     $ 10,415  

 

 

The accompanying Notes are integral to the Abbreviated Financial Statements.

 

 5

 

 

Abbreviated Statements of Net Product Sales Net of Direct Expenses for the Years Ended March 31, 2023 and 2022

 

    For the Twelve Months Ended
($ In Thousands)		  
             
    2023     2022  
Net product sales   $ 16,426     $ 15,607  
Cost of product sales   $ 8,077     $ 8,153  
Selling, general and administrative   $ 16,754     $ 20,334  
Research and development   $ 763     $ 706  
Intangible amortization & impairment   $ 0     $ 43,877  
Total direct expenses   $ 25,594     $ 73,070  
Net Product Sales Net of Direct Expenses   ($ 9,168 )   ($ 57,463 )

 

 

The accompanying Notes are integral to the Abbreviated Financial Statements.

 

 6

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022

 


(1)Background

 

Upsher-Smith Laboratories, LLC (the “Company” or “USL”) is a limited liability company focused on the development, manufacturing and commercialization of primarily generic pharmaceutical products. The Company offers a diverse array of products that help manage a wide range of conditions, from high blood pressure and high cholesterol, to migraine headaches and seizure disorders.

 

The Company markets and sells its proprietary products Tosymra® (Sumatriptan Nasal Spray) and Zembrace® Symtouch® (Sumatriptan Injection) (the “Product Lines”) in the United States. Both products are indicated for the acute treatment of migraine in adults.

 

On June 30, 2023 (the “Closing”), pursuant to an Asset Purchase Agreement entered into on June 23, 2023 with Upsher-Smith Laboratories LLC, (“Seller”), Tonix Pharmaceuticals Holding Corp. and its wholly-owned subsidiary, Tonix Medicines, Inc. (collectively, the “Purchaser”) completed the acquisition of Seller’s assets related to Zembrace® SymTouch® (sumatriptan injection) 3 mg (“Zembrace”) and Tosymra® (sumatriptan nasal spray) 10 mg (“Tosymra”) products (such businesses collectively, the “Business”) and certain inventory related to the Business for an aggregate purchase price of $26.5 million in cash, including certain deferred payments and subject to customary adjustments (such transaction, the “Acquisition”).

 

(2)Basis of Presentation

 

The accompanying abbreviated financial statements (Statements of Assets Acquired and Statements of Net Product Sales Net of Direct Expenses) (“Financial Statements”) for the Product Lines for the years ending March 31, 2023 and March 31, 2022 have been compiled by the Company in accordance with Rule 3-05 of Regulation S-X, Significant Acquisition Carveout, Financial Statement Reporting Requirements, as amended as the acquisition by Tonix meets the criteria established by the Securities and Exchange Commission to provide abbreviated financial statements in lieu of full financial statements of the acquired business. The acquired product lines do not represent a significant portion of USL’s business operations.

 

 7

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022

 

The statement of assets acquired only presents the assets acquired under the sale. There are no liabilities assumed in accordance with the agreement. The Financial Statements present only those revenues and expenses related to the certain assets to be acquired. The Financial Statements were derived from the historical accounting records of USL and were prepared in accordance with the basis of accounting described in these Notes, which is in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

 

It is impracticable to prepare complete financial statements related to Tosymra® and Zembrace® Symtouch® as USL never accounted for these Product Lines on a stand-alone basis or as a separate division or subsidiary, nor has the Company maintained distinct and separate books and records necessary to prepare full stand-alone or carve-out financial statements.

 

The operations of Tosymra® and Zembrace® Symtouch® Product Lines rely, to varying degrees, on USL for procurement, quality assurance, marketing, all sales activities, distribution, and facilities. These expenses have been allocated to the Tosymra® and Zembrace® Symtouch® Product Lines in these Financial Statements. These Financial Statements may not be indicative of the financial condition or results of operations of the Tosymra® and Zembrace® Symtouch® Product Lines on a stand-alone basis due to the reliance on USL.

 

The statements of net product sales net of direct expenses do not include corporate overhead (“G&A”), such as corporate management and communications, finance, human resources, regulatory, quality assurance, information technology and legal support as the Tosymra® and Zembrace® Symtouch® Product Lines never functioned on a stand-alone basis. Accordingly, no allocation of these support fees has been made to the Tosymra® and Zembrace® Symtouch® Product Lines.

 

During the twelve months ended March 31, 2023 and 2022 the Tosymra® and Zembrace® Symtouch® Product Lines did not have any stand-alone financing requirements, and any cash generated was collected at the consolidated level by USL. As the Tosymra® and Zembrace® Symtouch® Product Lines have historically been managed as part of the operations of USL and have not operated on a stand-alone basis, it is not practical to prepare historical cash flow information regarding the Tosymra® and Zembrace® Symtouch® Product Lines’ operating, investing and financing cash flows. As such, a statement of cash flows was not prepared.

 

 8

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022

 

(3)Certain Expenses and Allocations

 

Cost of product sales includes all costs incurred to produce Tosymra® and Zembrace® Symtouch® including variances and distribution. Variances represent the amount by which the actual production costs differ from expected cost. It also includes the cost related to obsolete materials.

 

Research and development costs include annual U.S. Food and Drug Administration’s (“FDA”) Prescription Drug User Fee Act (“PDUFA”) fees for the Tosymra® and Zembrace® Symtouch® Product Lines. PDUFA fees are paid annually and amortized straight-line over the corresponding period.

 

Selling, General and Administrative expenses include advertising and promotion, samples, copay assistance, patient authorization, along with allocated expenses primarily related to cost of labor and travel and entertainment. Costs associated with sales and marketing are expensed in the period incurred. Certain costs and expenses have been allocated by USL on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method. Management considers that such allocations have been made on a reasonable basis but may not necessarily be indicative of the costs that would have been incurred if the Tosymra® and Zembrace® Symtouch® Product Lines had been operated on a stand-alone basis for the periods presented.

 

(4)Summary of Significant Accounting Policies

 

(a)Use of Estimates

 

The preparation of these Abbreviated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. The estimates and associated assumptions are based on historical experience, judgments and various other factors that are believed to be reasonable under the circumstances but are inherently uncertain. Actual results may or may not differ from these estimates. Also, as discussed in Note 3, these Financial Statements include allocation and estimates that are not necessarily indicative of the amounts that would have resulted if the Tosymra® and Zembrace® Symtouch® Product Lines had operated on a stand-alone basis.

 

 9

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022

 

(b)Intangible Assets

 

Intangible assets represent the right to manufacture and/or offer for sale a product that has been approved by regulatory authorities. The value assigned to intangible assets is amortized using the straight-line method over the useful life of the asset with amortization recorded as a direct expense in the Abbreviated Financial Statement of Net Product Sales Net of Direct Expenses. Amortization periods for the product rights are based on the Company’s assessment of various factors impacting estimated useful lives and cash flows, typically 10 years. Such factors include the product’s position in its life cycle, the existence or absence of like products in the market, various other competitive and regulatory issues, and contractual terms. Significant changes to any of these factors may result in a reduction in the intangible’s useful life and an acceleration of related amortization expense.

 

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances (“triggering event”) such as asset utilization, legal factors or other matters indicate that the carrying value of those assets may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over the fair value, calculated using discounted future cash flows.

 

(c)Prepaid Assets

 

Prepaid assets include the prepaid portion of the FDA PDUFA fees for Tosymra® and Zembrace® Symtouch® that are paid annually and amortized straight-line over the corresponding period. It also includes advance payments related to Zembrace® Symtouch® raw materials and semi-finished goods.

 

 10

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022

 

The following table provides a breakdown of prepaid assets:

 

    As of March 31,  
    ($ in Thousands)  
    2023     2022  
                 
Zembrace® Symtouch® prepaid inventory   $ 789     $ 2,260  
Prepaid FDA PDUFA fees   $ 394     $ 370  
Total Prepaid Assets   $ 1,183     $ 2,630  

 

(d)Revenue Recognition

 

The Company recognizes revenues in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. The Company sells Tosymra® and Zembrace® Symtouch® to retail, chain and hospital pharmacies and key physician groups primarily by means of wholesale and drug chain distribution channels.

 

(i)Chargebacks

 

Chargebacks are amounts owed in the future to a wholesaler for the difference between the invoice price charged by the Company to the wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. Provisions for chargebacks are determined using historical chargeback experience or expected chargeback levels, wholesaler purchases and sales and estimated channel inventory information.

 

(ii) Rebates

 

The Company participates in certain government and specific sales rebate programs which provides discounted prescription drugs to qualified recipients.

 

Managed Care Rebates are processed in the quarter following the quarter in which they are earned. The managed care reporting entity submits utilization data after the end of the quarter and the Company processes the payment in accordance with contract terms. All rebates earned but not paid are estimated by the Company according to historical payments trended for market growth assumptions.

 

 11

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

And as and for the Twelve Months Ended March 31, 2023 and 2022

 

Medicaid and State Agency rebates are based upon historical experience of claims submitted by various states. The Company monitors Medicaid legislative changes to determine what impact such legislation may have on the provision for Medicaid rebates. The accrual of State Agency reserves is based on historical payment rates. There is an approximate three-month lag from the time of product sale until the rebate is paid.

 

Tri-Care represents a regionally managed health care program for active duty and retired members, dependents and survivors of the US military. The Tri-Care program supplements health care resources of the US military with civilian health care professionals for greater access and quality healthcare coverage. Through the Tri-Care program, the Company provides pharmaceuticals on a direct customer basis. Prices of pharmaceuticals sold under the Tri-Care program are pre-negotiated and a reserve amount is established to represent the proportionate rebate amount associated with product sales.

 

Coverage Gap refers to the Medicare prescription drug program and represents specifically the period between the initial Medicare Part D prescription drug program coverage limit and the catastrophic coverage threshold. Applicable pharmaceutical products sold during this coverage gap timeframe are discounted by the Company. Since the nature of the program is that coverage limits are reset at the beginning of the calendar year; the payments escalate each quarter as the participants reach the coverage limit before reaching the catastrophic coverage threshold. The Company has determined that the cost of this reserve will be viewed as an annual cost. Therefore, the accrual will be incurred evenly during the year with quarterly review of the liability based on payment trends and any revision to the projected annual cost.

 

(iii) Sales Discounts

 

Cash discounts related to early payment are treated as a reduction of revenue. The Company records revenue at 100% up front, less an immediate sales allowance against revenue at the time of the sale for the estimated discounts that will be taken by the customer. Consumer discounts represent programs the Company has in place to reduce costs to the patient. This includes copay buy down and eVoucher programs.

 

 12

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022

 

(iv) Sales Returns and Allowances

 

The Company maintains a return policy that allows customers to return product for credit. The estimate of the provision for future returns is based upon historical experience and current trends of actual customer returns based on a batch sell by date. Additionally, other factors are considered when estimating the current period return provision, including levels of inventory in the distribution channel, prior lot/batch returns as well as significant market changes which may impact future expected returns. Adjustments are made to the current provision for returns when data suggests product returns may differ from original estimates. The Company recognizes revenue, net of an allowance for estimated returns, at the time of sale.

 

The following table provides a breakdown of gross to net product sales:

 

    For the Twelve Months Ended
March 31,		  
    2023     2022  
Invoice product sales   $ 30,441     $ 32,329  
Chargebacks   ($ 390 )   ($ 448 )
Rebates   ($ 8,399 )   ($ 9,287 )
Sales discounts   ($ 3,486 )   ($ 3,581 )
Sales returns and allowances   ($ 1,740 )   ($ 3,406 )
Total gross-to-net adjustments:   ($ 14,015 )   ($ 16,722 )
Net Product Sales   $ 16,426     $ 15,607  

 

 

 13

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022

 

(5)Inventories

 

Inventories are stated at the lower of cost or net realizable value, with cost determined by the weighted average cost method.  Components of Tosymra® and Zembrace® Symtouch® are provided by a limited number of suppliers and product assembly and warehousing are outsourced to third parties. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on operations and financial results.

 

Inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventories and when, in the opinion of management, factors indicate that impairment has occurred, the Company establishes a reserve against the inventories' carrying value. The Company has an established process to reserve materials that the demand forecast indicates will expire prior to selling. Although the Company makes every effort to ensure the accuracy of forecasts of future product demand, any significant unanticipated decreases in demand could have a material impact on the carrying value of inventories and reported operating results.

 

A reserve is recorded for potentially excess, dated or obsolete inventories based on an analysis of inventory on-hand compared to forecasted future sales, which was $240 thousand and $321 thousand, as of March 31, 2023 and March 31, 2022, respectively.

 

Inventories consisted of the following:

 

    As of March 31,  
    ($ in Thousands)  
    2023     2022  
                 
Raw materials   $ 2,490     $ 1,461  
Semi-finished goods   $ 2,791     $ 3,929  
Finished goods   $ 3,371     $ 2,087  
Variance Adjustment Reserve   $ 820     $ 308  
Total Inventory   $ 9,472     $ 7,785  

 

 14

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022

 

(6)Intangible Assets, net

 

Intangible assets, net consist of the following:

 

    As of March 31,  
    ($ in Thousands)  
    2023     2022  
                 
Manufacturing product rights   $ 113,682     $ 113,682  
Accumulated amortization   ($ 21,650 )   ($ 21,650 )
Intangible impairment   ($ 92,032 )   ($ 92,032 )
Total Intangible Assets, net   $ 0     $ 0  

 

Manufacturing Product Rights represent licenses to manufacture and sell Tosymra® and Zembrace® Symtouch®. During the year ended March 31, 2022, the Company identified a triggering event pertaining to the Manufacturing Product Rights intangible assets. An independent valuation firm was engaged to perform a valuation analysis. The findings of the independent valuation firm’s analysis resulted in USL recording impairment expense of $39.4 million related to Tosymra® and Zembrace®. This is reflected as intangible impairment within the Intangible assets, net schedule included above and is in addition to the $52.6 million impairment previously recorded.

 

 15

 

 

TOSYMRA® AND Zembrace® Symtouch®

 

Product Lines of Upsher-Smith Laboratories LLC.

 

Notes to Abbreviated Financial Statements

 

As of and for the Twelve Months Ended March 31, 2023 and 2022 

 

Intangible asset amortization, prior to the impairment charge referred to above, was $4.4 million for the year ended March 31, 2022. 

 

(7) Subsequent Events

 

USL has evaluated subsequent events through July 18, 2023, the date the Abbreviated Financial Statements were available to be issued, and determined there are no other items to disclose.

 

 16

 

 

 EX-99.02 4 ex99-02.htm UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

 

Tonix Pharmaceuticals Holding Corp, Inc. 8-K

Exhibit 99.02

 

Tonix Pharmaceuticals Holding Corp.

Unaudited Pro Forma Condensed Combined Financial Information

 

On June 30, 2023 (the “Closing”), pursuant to an Asset Purchase Agreement entered into on June 23, 2023 with Upsher-Smith Laboratories LLC, (“Seller”), Tonix Pharmaceuticals Holding Corp. and its wholly-owned subsidiary, Tonix Medicines, Inc. (collectively, the “Company” or “Purchaser”) completed the acquisition of Seller’s assets related to Zembrace® SymTouch® (sumatriptan injection) 3 mg (“Zembrace”) and Tosymra® (sumatriptan nasal spray) 10 mg (“Tosymra”) products (such businesses collectively, the “Business”) and certain inventory related to the Business for an aggregate purchase price of $26.5 million in cash, including certain deferred payments and subject to customary adjustments (such transaction, the “Acquisition”).

The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X. The unaudited pro forma adjustments reflecting the Acquisition have been prepared in accordance with Accounting Standards Codification 805, Business Combinations ("ASC 805") and reflect the preliminary allocation of the estimated consideration to the assets acquired based upon their estimated fair values, using the assumptions set forth in the notes to the unaudited pro forma condensed combined financial information.

The unaudited pro forma condensed combined balance sheet as of March 31, 2023 combines the historical balance sheet of the Company and the abbreviated statement of assets acquired of the Business as of March 31, 2023 on a pro forma basis as if the Acquisition had been consummated on March 31, 2023. While the Company and Seller have different fiscal period ends, Rule 11-02(c)(3) of Regulation S-X permits fiscal period ends within one quarter between the acquirer and acquiree to be combined for the purposes of presenting pro forma financial information. Accordingly, the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 combines the historical statement of operations of the Company for the year ended December 31, 2022 and the abbreviated statement of net product sales net of direct expenses of the Business for the year ended March 31, 2023 on a pro forma basis as if the Acquisition had been consummated on January 1, 2022. The unaudited pro forma condensed combined statement of operations for the three months ended March 31, 2023 combines the historical statement of operations of the Company for the three months ended March 31, 2023 and the net product sales net of direct expenses of the Business for the three months ended March 31, 2023 on a pro forma basis as if the Acquisition had been consummated on January 1, 2022, the beginning of the earliest period presented.

Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial statements are described in the accompanying notes. The unaudited pro forma adjustments represent management’s preliminary estimates based on information available as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes available and analyses are performed. The unaudited pro forma condensed combined financial statements should be read in conjunction with the Company’s historical consolidated financial statements and the historical audited abbreviated financial statements of the Business and accompanying notes filed as an exhibit to this Form 8-K.

The following unaudited pro forma condensed combined financial statements are provided for illustrative purposes only and are based on available information and assumptions that the Company believes are reasonable. They do not purport to represent what the actual combined results of operations or the combined financial position would have been had the Acquisition occurred on the dates indicated, or on any other date, nor are they necessarily indicative of the Company’s future combined results of operations or the combined financial position after the Acquisition. The Company’s actual financial position and results of operations after the Acquisition will differ, perhaps significantly, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value not currently identified, and changes in operating results of the Company and the Business following the date of the unaudited pro forma condensed combined financial statements. The unaudited pro forma condensed combined financial information includes certain reclassifications to conform the historical financial information prepared by Seller to the Company’s presentation.

 

 

 

 

Tonix Pharmaceuticals Holding Corp.

Unaudited Pro Forma Condensed Combined Balance Sheet

As of March 31, 2023

(Amounts in thousands, except share and per share amounts)

 

 

   Historical   Pro Forma 
   Tonix
Pharmaceuticals
Holding Corp.		   Assets
Acquired from
Upsher-Smith
Laboratories LLC		   Transaction
Accounting
Adjustments
(Note 3)		   Pro Forma
Combined		 
ASSETS                
Current assets:                    
Cash and cash equivalents  $71,975   $—   $(22,174)(a)  $49,801 
Inventory   —    9,472    4,228(b)   13,700 
Prepaid expenses and other   11,751    1,183    574(c)   13,508 
Total current assets   83,726    10,655    (17,372)   77,009 
                     
Property and equipment, net   93,991    —    —    93,991 
                     
Right of use assets, net   986    —    —    986 
Intangible assets, net   —    —    10,100(d)   10,100 
Goodwill   —    —    965(e)   965 
Other non-current assets   385    —    —    385 
Total assets  $179,088   $10,655   $(6,307)  $183,436 
                     
LIABILITIES AND STOCKHOLDERS' EQUITY                    
Current liabilities:                    
Accounts payable  $8,016   $—   $—   $8,016 
Accrued expenses and other current liabilities   4,619    —    4,348(a)   8,967 
Lease liability, current   438    —    —    438 
Total current liabilities   13,073    —    4,348    17,421 
                     
Lease liability, net of current   588    —    —    588 
Total liabilities   13,661    —    4,348    18,009 
                     
Stockholders’ equity:                    
Preferred stock:                    
Series B Convertible Preferred Stock   —    —    —    — 
Series A Convertible Preferred Stock   —    —    —    — 
Common stock   64    —    —    64 
Additional paid-in capital   682,566    —    —    682,566 
Accumulated deficit   (516,992)   —    —    (516,992)
Accumulated other comprehensive loss   (211)   —    —    (211)
Historical implied equity/net assets acquired   —    10,655    (10,655)   — 
Total stockholders’ equity   165,427    10,655    (10,655)   165,427 
Total liabilities and stockholders’ equity  $179,088   $10,655   $(6,307)  $183,436 

 

See accompanying notes to unaudited pro forma condensed combined financial statements.

 

 

 

 

Tonix Pharmaceuticals Holding Corp.

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Three Months Ended March 31, 2023

(Amounts in thousands, except share and per share amounts)

 

 

    Historical     Pro Forma    
    Tonix Pharmaceuticals Holding Corp     Upsher-Smith Laboratories LLC Net Product Sales Net of Direct Expenses     Transaction
Accounting
Adjustments
(Note 3)		     Pro Forma Combined    
Net Product Sales   $ —     $ 4,078     $ —     $ 4,078    
Cost of Sales     —       (2,321 )     —       (2,321 )  
Gross Profit     —       1,757       —       1,757    
                                   
COSTS AND EXPENSES:                                  
Research and development     26,511       197       —       26,708    
Amortization expense     —       —       214 (d)     214    
General and administrative     7,391       2,790       —       10,181    
      33,902       2,987       214       37,103    
                                   
Operating loss     (33,902 )     (1,230 )     (214 )     (35,346 )  
                                   
Interest income     897       —       —       897    
                                   
Net loss   $ (33,005 )   $ (1,230 )   $ (214 )   $ (34,449 )  
                                   
Net loss per common share, basic and diluted   $ (3.21 )                   $ (3.35 ) Note 4
                                   
Weighted average common shares outstanding, basic and diluted     10,268,500                       10,268,500   Note 4

 

See accompanying notes to unaudited pro forma condensed combined financial statements.

 

 

 

 

Tonix Pharmaceuticals Holding Corp.

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Year Ended December 31, 2022

(Amounts in thousands, except share and per share amounts)

 

    Historical     Pro Forma    
    Tonix Pharmaceuticals Holding Corp.     Upsher-Smith Laboratories LLC Net Product Sales Net of Direct Expenses     Transaction
Accounting
Adjustments
(Note 3)		     Pro Forma Combined    
Net Product Sales   $ —     $ 16,426     $ —     $ 16,426    
Cost of Sales     —       (8,077 )     (3,935 )(b)     (12,012 )  
Gross Profit     —       8,349       (3,935 )     4,414    
                                   
COSTS AND EXPENSES:                                  
Research and development     81,876       763       —       82,639    
Amortization expense     —       —       856 (d)     856    
General and administrative     30,215       16,754       —       46,969    
      112,091       17,517       856       130,464    
                                   
Operating loss     (112,091 )     (9,168 )     (4,791 )     (126,050 )  
                                   
Interest income     1,873       —       —       1,873    
                                   
Net loss   $ (110,218 )   $ (9,168 )   $ (4,791 )   $ (124,177 )  
                                   
Preferred stock deemed dividend     6,659       —       —       6,659    
                                   
Net loss available to common stockholders   $ (116,877 )   $ (9,168 )   $ (4,791 )   $ (130,836 )  
                                   
Net loss per common share, basic and diluted   $ (20.01 )                   $ (22.40 ) Note 4
                                   
Weighted average common shares outstanding, basic and diluted     5,841,447                       5,841,447   Note 4

 

 

See accompanying notes to unaudited pro forma condensed combined financial statements.

 

 

 

 

Tonix Pharmaceuticals Holding Corp.

Notes to Unaudited Pro Forma Condensed Combined Financial Statements

 

1.Basis of Pro Forma Presentation

 

The financial statements included in the unaudited pro forma condensed combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of SEC Regulation S-X.

 

The unaudited pro forma condensed combined balance sheet as of March 31, 2023 combines the historical balance sheet of the Company and the abbreviated statement of assets acquired of the Business as of March 31, 2023 on a pro forma basis as if the Acquisition had been consummated on March 31, 2023. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 combines the historical statement of operations of the Company for the year ended December 31, 2022 and the abbreviated statement of net product sales net of direct expenses of the Business for the fiscal year ended March 31, 2023 on a pro forma basis as if the Acquisition had been consummated on January 1, 2022. The unaudited pro forma condensed combined statement of operations for the three months ended March 31, 2023 combines the historical statement of operations of the Company for the three months ended March 31, 2023 and the net product sales net of direct expenses of the Business for the three months ended March 31, 2023 on a pro forma basis as if the Acquisition had been consummated on January 1, 2022, the beginning of the earliest period presented.

 

The unaudited pro forma condensed combined financial statements and related adjustments are based on available information and certain assumptions that management believes are reasonable. However, actual results may differ from those reflected in these statements. The unaudited pro forma condensed combined financial statements do not purport to represent what the combined results of operations would have been if the Acquisition had actually occurred on the dates indicated above, nor are they indicative of the Company’s future results of operations or the combined financial position after the Acquisition.

 

These unaudited pro forma condensed combined financial statements should be read in conjunction with the Company’s historical financial statements as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with Securities and Exchange Commission (“SEC”) on March 13, 2023, the Company’s historical financial statements as of and for the three months ended March 31, 2023 included in the Company’s Form 10-Q filed with the SEC on May 8, 2023, as well as the historical audited abbreviated financial statements of the Business and accompanying notes filed as Exhibit 99.01 to this Form 8-K.

 

In accordance with current accounting guidance, the assets acquired have been measured at fair value by the Company and the difference between these assets and the purchase price has been recorded as goodwill. The fair value measurements utilize estimates based on key assumptions of the acquisition, and historical and current market data. These fair value measurements and the related pro forma adjustments included herein may be revised as additional information becomes available and as additional analyses are performed. Therefore, the final purchase price allocation may differ materially from the information presented. For the purpose of measuring the estimated fair value of the assets acquired, the Company has applied the accounting guidance for fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

For the purposes of presenting the unaudited pro forma condensed combined financial statements, certain balances within the statement of assets acquired and statements of net product sales net of direct expenses of the Business have been reclassified into line items and included in the subtotals to conform with the historical presentation in the Company’s financial statements.

 

2.Preliminary Purchase Price Allocation

 

The Company has performed a preliminary analysis of the fair value of the assets acquired of the Business. The Company has estimated the allocation of the purchase consideration to assets acquired based on their respective estimated fair values. The preliminary purchase price allocation has been used to prepare the Transaction Accounting Adjustments in the accompanying unaudited pro forma condensed combined balance sheet and condensed combined statements of operations. For purposes of preparing the unaudited pro forma condensed combined financial statements, the estimated fair value amounts and corresponding purchase price allocation incorporate the amount of the Business assets as of March 31, 2023, the required period under Article 11. These amounts are different than those on hand upon Closing of the Acquisition. The final purchase price allocation will incorporate the Business assets on hand upon Closing of the Acquisition and will be determined when the Company has completed its detailed valuations and necessary calculations.

 

 

 

 

The following table represents a preliminary allocation of the estimated purchase consideration to the assets acquired (in thousands):

 

Preliminary purchase price allocation  Amount 
Inventory  $13,700 
Prepaid expenses and other   1,757 
Intangible assets, net   10,100 
Goodwill   965 
Total consideration  $26,522 

 

The acquired inventory consists of Seller’s raw materials, semi-finished goods, and finished goods inventory as of the Closing date. The fair value was determined based on the estimated selling price of the inventory, less the estimated total costs to complete, disposal effort and holding costs.

 

The identifiable intangible assets acquired include the developed technology related to Zembrace and Tosymra, which includes the value associated with the acquired patents, customer relationships, and trademarks and trade names associated with the technology. The developed technology intangible assets were valued as composite assets under the premise that each asset is reliant on one another to generate cash flow, is not considered separable from the technology, and are assumed to have similar useful lives. The composite intangible assets for Zembrace and Tosymra were valued using a multi-period excess earnings method and will be amortized over a remaining useful life of 14 years and 9 years, respectively.

 

The fair value of goodwill represents expected synergies from combining operations, intangible assets that do not qualify for separate recognition, and other factors.

 

3.Transaction Accounting Adjustments

 

The Company anticipates accounting for the Acquisition as a business combination in accordance with Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 805, Business Combinations, and Accounting Standards Update (“ASU”) No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, whereby the Company recognized the assets acquired at their estimated fair values on the acquisition date. The excess of the purchase price over the estimated fair values of net assets acquired has been recorded as goodwill. The Transaction Accounting Adjustments have been prepared as if the Acquisition had taken place on March 31, 2023 in the case of the Unaudited Pro Forma Condensed Combined Balance Sheet, and on January 1, 2022 in the case of the Unaudited Pro Forma Condensed Combined Statements of Operations.

 

For pro forma purposes, the Company has preliminarily allocated the purchase consideration to the assets acquired based on their respective estimated fair values. Therefore, as discussed further below, the purchase price allocation is provisional and will be finalized after the Company receives and reviews all available data and completes its detailed valuation analysis.

 

The following adjustments have been reflected in the unaudited pro forma condensed combined financial information:

 

(a)Represents estimated total preliminary consideration for the Acquisition of approximately $26.5 million, of which approximately $22.2 million was paid in cash as of the Closing. The closing cash consideration was later adjusted upwards by approximately $1.3 million upon the determination of the value of the acquired inventory on hand as of June 30, 2023. The inventory adjustment payment is expected to be settled in the third quarter of 2023. In addition, the Company agreed to pay a deferred cash payment of $3.0 million, anticipated to be paid approximately six months following the Closing. The purchase consideration is preliminary and subject to certain customary adjustments. The following table summarizes the components of the purchase consideration (in thousands):

 

Preliminary purchase consideration  Amount 
Closing cash consideration  $22,174 
Inventory adjustment payment liability   1,348 
Deferred payment liability   3,000 
Purchase price to be allocated  $26,522 

 

 

 

 

(b)The upward adjustment to inventory of approximately $4.2 million reflects the preliminary step-up to fair value of the acquired inventory of the Business as well as a $0.3 million increase in inventory on hand as of June 30, 2023 as compared to March 31, 2023. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 is also adjusted to increase Cost of Sales by $3.9 million, the amount attributable to the fair value increase, as the inventory is expected to be sold within 12 months of the acquisition date. Accordingly, this adjustment is not expected to affect the Company’s results of operations beyond 12 months after the acquisition date.

(c)Includes an upward adjustment of approximately $0.8 million related to additional acquired prepayments for inventory at the Closing, partially offset by a downward adjustment of approximately $0.2 million for certain acquired prepaid assets to reflect three months less of contractual benefits.

(d)As part of the preliminary valuation analysis, the Company determined the fair value of the two composite intangible assets of $6.7 million and $3.4 million related to Zembrace and Tosymra, respectively, for a total fair value adjustment of $10.1 million. These acquired intangible assets will be amortized over a remaining useful life of 14 years and 9 years, respectively. Accordingly, the adjustment to the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 reflects one year of straight-line amortization expense. The adjustment to the unaudited pro forma condensed combined statement of operations for the three months ended March 31, 2023 reflects one quarter of straight-line amortization expense of these intangibles.

(e)Reflects goodwill resulting from the Acquisition based on the preliminary purchase price allocation in Note 2 above.

 

4.Net Loss per Common Share

Net loss per common share was calculated giving effects to the Transaction Accounting Adjustments outlined in Note 3 using the Company’s historical weighted average shares outstanding and diluted weighted average shares outstanding, adjusted to reflect the Company’s reverse stock split at a ratio of 1-for-6.25 effective at 12:01 a.m., Eastern Time, on May 10, 2023, as previously announced on the Company’s Form 8-K filed with the SEC on May 9, 2023. There were no shares or dilutive securities issued in connection with the Acquisition.

 

 

 EX-101.SCH 5 tnxp-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 tnxp-20230630_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 tnxp-20230630_pre.xml XBRL PRESENTATION FILE GRAPHIC 8 ex23-01_img01.jpg GRAPHIC begin 644 ex23-01_img01.jpg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end GRAPHIC 9 ex9901001.jpg GRAPHIC begin 644 ex9901001.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jun. 30, 2023
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 1 to the Original 8-K is being filed to provide the required financial statements under Rule 3-05 of Regulation S-X with respect to the Acquisition.
Document Period End Date Jun. 30, 2023
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 11 tnxp_8ka-063023_htm.xml IDEA: XBRL DOCUMENT 0001430306 2023-06-30 2023-06-30 iso4217:USD shares iso4217:USD shares 0001430306 true This Amendment No. 1 to the Original 8-K is being filed to provide the required financial statements under Rule 3-05 of Regulation S-X with respect to the Acquisition. 8-K/A 2023-06-30 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://TNXP/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp_8ka-063023.htm ex23-01.htm ex99-01.htm ex99-02.htm tnxp-20230630.xsd tnxp-20230630_lab.xml tnxp-20230630_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tnxp_8ka-063023.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tnxp_8ka-063023.htm" ] }, "labelLink": { "local": [ "tnxp-20230630_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20230630_pre.xml" ] }, "schema": { "local": [ "tnxp-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "TNXP", "nsuri": "http://TNXP/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tnxp_8ka-063023.htm", "contextRef": "From2023-06-30to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://TNXP/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tnxp_8ka-063023.htm", "contextRef": "From2023-06-30to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://TNXP/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0001387131-23-008497-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-23-008497-xbrl.zip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end